- Home
- BAOS vs MBRX Comparison
BAOS vs MBRX Comparison
Compare BAOS & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAOS | MBRX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 10.1M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BAOS | MBRX |
|---|---|---|
| Price | $0.24 | $0.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 4.6M | 1.1M |
| Earning Date | 04-30-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.16 |
| 52 Week High | $5.21 | $7.98 |
Technical Indicators
Market Signals| Indicator | BAOS | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 29.04 | 35.94 |
| Support Level | N/A | $0.50 |
| Resistance Level | $0.36 | $0.67 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 14.75 | 3.96 |
Price Performance
Historical ComparisonAbout BAOS Baosheng Media Group Holdings
Baosheng Media Group Holdings Ltd is a China-based online marketing solution provider. The company provides internet marketing, short-video and V-log marketing, content production and operation, e-commerce marketing, data platform services, and AI technology-related services. It also offers customized marketing solutions and channel marketing services through partnerships with internet platforms such as Tencent, Alibaba, ByteDance, and Kuaishou.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.